Senvera Therapeutics, Inc. A Curie.Bio Company

About

Senvera Therapeutics' mission is to translate compelling foundational science into transformative regenerative therapies for patients living with age-related olfactory loss, or presbyosmia, a highly prevalent disease of ageing associated with increased morbidity and 10-year mortality, and for which there are no approved therapies. Our strategy seeks to exploit a deep understanding of pathology and molecular mechanisms that regulate the peripheral olfactory stem cell niche. Rhino Therapeutics, Inc is funded by Curie.Bio. For more information please visit https://curie.bio/

Product

Value proposition

We develop regenerative therapies that translate cutting-edge science into meaningful solutions for patients with no current treatment options for olfactory loss.

Target customers

partnerships and investors in biotechnology and pharmaceutical development

Founders

• Graham Wynne — Founder, CTO
• Andy Mulvaney — Founding CEO
• Kleanthis G. Xanthopoulos — President & Chief Executive Officer

Categories

Products

Key features

Technologies

Target conditions

Care settings

Partnerships

Investors

News

• Chad Viergever - Corp Dev at Senvera Therapeutics | USC MBA · 2025-12-15T00:00:00.000Z
• Curie.Bio · 2025-09-20T00:00:00.000Z
• Biopharma Insights - November 2025 - LinkedIn · 2025-11-07T00:00:00.000Z
• Analyzing Biotech Financings Beyond Headline Numbers - LinkedIn · 2026-04-27T00:00:00.000Z
• Addressing Antimicrobial Resistance with Innovative Science · 2026-04-21T00:00:00.000Z
• Interview with Rory Mullen - Head of Biopharma and Food, IDA Ireland · 2026-05-29T00:00:00.000Z

Browse related software

• Clinic software in MA
• Clinic software in Boston
• BioTech software
• Regenerative Medicine software
• Neuroscience software
• All clinic software companies A–Z

More links